Alternatives to hazard ratios for comparing the efficacy or safety of therapies in noninferiority studies

Annals of Internal Medicine

Volumn 163, Issue 2, 2015, Pages 127-134

  Uno, Hajime ^a   Wittes, Janet ^b   Fu, Haoda ^c   Solomon, Scott D ^d   Claggett, Brian ^d   Tian, Lu ^e   Cai, Tianxi ^f   Pfeffer, Marc A ^d   Evans, Scott R ^f   Wei, Lee Jen ^f  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b University of Iowa   (United States)

^c ELI LILLY AND COMPANY   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; SAXAGLIPTIN;

ACCURACY; ALTERNATIVE MEDICINE; ARTICLE; ATTRIBUTABLE RISK; BRAIN ISCHEMIA; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL STUDY; DECISION MAKING; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FOLLOW UP; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HUMAN; INCIDENCE; LONG TERM CARE; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONINFERIORITY STUDY; PAIN; PRIORITY JOURNAL; SAMPLE SIZE; SURVIVAL TIME; ADVERSE DRUG REACTION; CLINICAL TRIAL (TOPIC); DRUG THERAPY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HUMANS; PROPORTIONAL HAZARDS MODELS; RESEARCH DESIGN; SAMPLE SIZE; TREATMENT OUTCOME;

EID: 84938245762     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M14-1741     Document Type: Article

References (27)

1. Hernán MA. The hazards of hazard ratios. Epidemiology. 2010;21:13-5. [PMID: 20010207] doi:10.1097/EDE.0b013e3181c1ea43
2. Muñoz A, Mongilardi N, Checkley W. Multilevel competing risks in the evaluation of nosocomial infections: time to move on from proportional hazards and even from hazards altogether. Crit Care. 2014;18:146. [PMID: 25042281] doi:10.1186/cc13892
3. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014;32:2380-5. [PMID: 24982461] doi:10.1200/JCO.2014.55.2208
4. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med. 2003;22:169-86. [PMID: 12520555]
5. Head SJ, Kaul S, Bogers AJ, Kappetein AP. Non-inferiority study design: lessons to be learned from cardiovascular trials. Eur Heart J. 2012;33:1318-24. [PMID: 22564354] doi:10.1093/eurheartj/ehs099
6. Schumi J, Wittes JT. Through the looking glass: understanding non-inferiority. Trials 2011;12:106-18.
7. Solomon SD, Pfeffer MA, McMurray JJ, Fowler R, Finn P, Levin B, et al; APC and PreSAP Trial Investigators. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation. 2006;114:1028-35. [PMID: 16943394]
8. Cox DR. Regression models and life-tables. J RStat Soc Series B Stat Methodol. 1972;34:187-220.
9. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26. [PMID: 23992601] doi:10.1056/NEJMoa1307684
10. U. S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research. Guidance for industry diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Accessed at www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071627.pdf on 14 February 2014.
11. Hirshberg B, Raz I. Impact of the U. S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl 2:S101-6. [PMID: 21525438] doi:10.2337/dc11-s202
12. Hirshberg B, Katz A. Cardiovascular outcome studies with novel antidiabetes agents: scientific and operational considerations. Diabetes Care. 2013;36 Suppl 2:S253-8. [PMID: 23882054] doi:10.2337/dcS13-2041
13. Hiatt WR, Kaul S, Smith RJ. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med. 2013;369:1285-7. [PMID: 23992603] doi:10.1056/NEJMp1309610
14. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-35. [PMID: 23992602] doi:10.1056/NEJMoa1305889
15. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York: J Wiley; 1991.
16. Su JQ, Wei LJ. Nonparametric estimation for the difference or ratio of median failure times. Biometrics. 1993;49:603-7. [PMID: 8369391]
17. Wei LJ. The accelerated failure time model: a useful alternative to the Cox regression model in survival analysis. Stat Med. 1992;11:1871-9. [PMID: 1480879]
18. Zucker DM. Restricted mean life with covariates: modification and extension of a useful survival analysis method. J Am Stat Assoc. 1998;93:702-9.
19. Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med. 2011;30:2409-21. [PMID: 21611958] doi:10.1002/sim.4274
20. Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, et al. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials. 2012;9:570-7. [PMID: 22914867] doi:10.1177/1740774512455464
21. Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152. [PMID: 24314264] doi:10.1186/1471-2288-13-152
22. Tian L, Zhao L, Wei LJ. Predicting the restricted mean event time with the subject's baseline covariates in survival analysis. Biostatistics. 2014;15:222-33. [PMID: 24292992] doi:10.1093/biostatistics/kxt050
23. Klein JP, Gerster M, Andersen PK, Tarima S, Perme MP. SAS and R functions to compute pseudo-values for censored data regression. Comput Methods Programs Biomed. 2008;89:289-300. [PMID: 18199521] doi:10.1016/j.cmpb.2007.11.017
24. Parner ET, Andersen PK. Regression analysis of censored data using pseudo-observations. Stata J. 2010;10:408-22.
25. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9. [PMID: 22297116] doi:10.1186/1471-2288-12-9
26. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, De Zeeuw D, Eckardt KU, et al; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009;361:2019-32. [PMID: 19880844] doi:10.1056/NEJMoa0907845
27. Parzen MI, Wei LJ, Ying Z. Simultaneous confidence intervals for the difference of two survival functions. Scand J Stat. 1997;24:309-14.